Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker-Reference-Cited by-同舟云学术

Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker

Published:2018-07 Issue:7 Volume:12 Page:813-820
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

O'Conor Christopher J¹,Chen Tiffany¹,González Iván¹,Cao Dengfeng¹,Peng Yan²

Affiliation:

1. Department of Pathology & Immunology, Washington University in St Louis, St Louis, MO 63110, USA

2. Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA

Abstract

Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel strategy for the treatment of TNBC. This review highlights the current understanding of breast cancer stem cells in TNBC, with focus on CD44+/CD24- and ALDH1+ breast cancer stem cells. It is our hope that this work provides insight into the potential role of cancer stem cells in the prognostication and therapeutic targeting of TNBC.

Publisher

Future Medicine Ltd

Subject

Biochemistry, medical,Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2017-0398

Reference56 articles.

1. Estimating the world cancer burden: Globocan 2000

2. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

3. Targeted therapies for ER+/HER2- metastatic breast cancer

4. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

5. Molecular portraits of human breast tumours

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TET1 regulates stem cell properties and cell cycle of Cancer stem cells in triple-negative breast cancer via DNA demethylation;Biochemical Pharmacology;2024-01

2. The clinical significance of the expression of PROM1/CD133, NOTCH2 and CDK4 in triple-negative breast cancer;2023-12-11

3. Transdermal therapeutic systems in breast cancer therapy;Journal of Drug Delivery Science and Technology;2023-12

4. CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1;Breast Cancer: Targets and Therapy;2023-12

5. Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells;BMC Cancer;2023-11-13